Group 1 - The company held its 29th meeting of the 11th Board of Directors on December 5, 2025, via telecommunication voting, with all 11 directors present, complying with relevant laws and regulations [1] - The Board approved an adjustment to the expected related party transactions for 2025 with its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., increasing the total expected amount to RMB 166 million, with an additional RMB 37.6 million [2] - The expected amount for energy services was adjusted from RMB 11.8 million to RMB 16 million, and for other labor services from RMB 11.6 million to RMB 45 million, while the amounts for procurement and leasing remained unchanged [2] Group 2 - The proposal involves related party transactions as Health元药业集团股份有限公司 holds a 22.58% stake in Lizhu Monoclonal Antibody, with certain directors abstaining from voting due to conflicts of interest [3] - The proposal was reviewed and approved by the independent directors in a special meeting, with unanimous consent from all independent directors [4] - The voting results showed 7 votes in favor, 0 against, and 0 abstentions [5]
丽珠医药集团股份有限公司 第十一届董事会第二十九次会议决议公告